Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785995 | 1.00 | CHAT (0.47) | CHATHRH4SMN1; SMN2RELACYP1A2 | |
| SCHEMBL9323561 | 0.85 | LMNA (0.50) | SMN1; SMN2RELACYP2C9CYP2D6HIF1A | |
| SCHEMBL9323556 | 0.85 | LMNA (0.50) | SMN1; SMN2RELACYP2C9CYP2D6HIF1A | |
| SCHEMBL630672 | 0.85 | NFE2L2 (0.53) | HRH4SMN1; SMN2RELAADORA2AKDM4E | |
| SCHEMBL630673 | 0.85 | NFE2L2 (0.53) | HRH4SMN1; SMN2RELAADORA2AKDM4E | |
| SCHEMBL5789877 | 0.85 | HRH4 (0.45) | CHATHRH4SMN1; SMN2RELACYP1A2 | |
| SCHEMBL5789872 | 0.85 | HRH4 (0.45) | CHATHRH4SMN1; SMN2RELACYP1A2 | |
| SCHEMBL5788957 | 0.83 | AHR (0.42) | SMN1; SMN2CYP1A2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL5788959 | 0.83 | AHR (0.42) | SMN1; SMN2CYP1A2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL5790627 | 0.82 | RELA (0.53) | RELACYP1A2KMT2AFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335906-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| CN-1473156-A | Pyrimidine derivatives and their use as neuropeptide y receptor ligands | - | 2004-02-04 | — | — | CN | disclosed |
| US-6657060-B2 | Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia | HOFFMAN-LA ROCHE INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1335906-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-20020086858-A1 | Pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | US | disclosed |
| WO-2002038551-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086858-A1 | Pyrimidine derivatives | NPY1R, NPY5R, NPY4R | CHAT 4097/4885HRH4 410/4885SMN1; SMN2 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.